Wen Li, PhD

Title(s)Associate Researcher, Radiology
SchoolSchool of Medicine
Address550 16th Street, #7356
San Francisco CA 94158
Phone415-885-3764
PronounsShe/Her/Hers
ORCID ORCID Icon0000-0001-6584-363X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Shanghai Jiao Tong UniversityB.S.2001Biomedical Engineering
    Shanghai Jiao Tong UniversityM.S.2004Biomedical Engineering
    University of IowaPh.D.2012Biomedical Engineering
    Children's National Medical CenterPostdoctoral Training2013Sheikh Zayed Institute for Pediatric Surgical Innovation
    University of California San FranciscoPostdoctoral Training2019Breast Cancer Imaging
    Collapse Awards and Honors
    Shanghai Jiao Tong University1997  - 2001Excellent Academic Scholarship
    University of Shanghai for Science and Technology2005  - 2006Young Scholar Research Award
    Shanghai Municipal Education Commission2006  - 2007Young Investigator Research Award
    University of Shanghai for Science and Technology2007Outstanding Young Scholar
    Image Processing Winter School at the University of Sao Paulo, Brazil2010Travel Award
    ISMRM 23rd Annual Meeting & Exhibition2015Educational Stipend Award
    ISMRM 24th Annual Meeting & Exhibition2016Educational Stipend Award
    San Antonio Breast Cancer Symposium2016Clinical Scholar Award
    ISMRM 26th Annual Meeting & Exhibition2018Educational Stipend Award
    Joint Annual Meeting ISMRM-ESMRMB2018Summa Cum Laude Merit Award
    ISMRM 27th Annual Meeting & Exhibition2019Educational Stipend Award
    ISMRM 27th Annual Meeting & Exhibition2019Magna Cum Laude Merit Award

    Collapse Overview 
    Collapse Overview
    Dr. Li is an expert in biomedical imaging analysis. At UCSF, her research is focused on optimizing and integrating quantitative imaging (DCE-MRI, DW-MRI, MammiPET) metrics as biomarkers in predicting treatment response for patients with breast cancer. Dr. Li's research interests include quantitative imaging methodology in cancer, tumor heterogeneity in biomedical images, prediction model for treatment response in systematic chemotherapy, machine learning in medicine, etc.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer
    NIH/NCI R01CA255442Dec 3, 2020 - Dec 2, 2025
    Role: Principal Investigator
    Description: The goal of this study is to develop strategies for combining liquid biopsy and MRI-based measures of tumor burden to build robust predictors of response and metastatic recurrence, with the ultimate goal of improving outcomes in high-risk early breast cancer patients receiving NAC.

    Collapse Featured Content 
    Collapse Featured Presentations

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
      Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
      Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
      1. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Sep 14. Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277671.
        View in: PubMed   Mentions:    Fields:    
      2. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Sep 14. Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. PMID: 39277672.
        View in: PubMed   Mentions:    Fields:    
      3. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2444-2451. Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 38470545; PMCID: PMC11147708.
        View in: PubMed   Mentions:    Fields:    Translation:Humans
      4. Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes. Cancers (Basel). 2024 May 15; 16(10). Magbanua MJM, Li W, van 't Veer LJ. PMID: 38791958; PMCID: PMC11120531.
        View in: PubMed   Mentions:
      5. 18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy. Radiol Imaging Cancer. 2024 03; 6(2):e230082. Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM. PMID: 38551406; PMCID: PMC10988337.
        View in: PubMed   Mentions: 1     Fields:    Translation:Humans
      6. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge. Radiol Imaging Cancer. 2024 01; 6(1):e230033. Li W, Partridge SC, Newitt DC, Steingrimsson J, Marques HS, Bolan PJ, Hirano M, Bearce BA, Kalpathy-Cramer J, Boss MA, Teng X, Zhang J, Cai J, Kontos D, Cohen EA, Mankowski WC, Liu M, Ha R, Pellicer-Valero OJ, Maier-Hein K, Rabinovici-Cohen S, Tlusty T, Ozery-Flato M, Parekh VS, Jacobs MA, Yan R, Sung K, Kazerouni AS, DiCarlo JC, Yankeelov TE, Chenevert TL, Hylton NM. PMID: 38180338; PMCID: PMC10825718.
        View in: PubMed   Mentions: 1     Fields:    Translation:Humans
      7. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment. Radiol Imaging Cancer. 2023 07; 5(4):e220126. Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network. PMID: 37505107; PMCID: PMC10413289.
        View in: PubMed   Mentions: 2     Fields:    Translation:Humans
      8. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4. Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. PMID: 37146605; PMCID: PMC10330514.
        View in: PubMed   Mentions: 24     Fields:    Translation:Humans
      9. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. Cancers (Basel). 2022 Sep 13; 14(18). Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM. PMID: 36139594; PMCID: PMC9497087.
        View in: PubMed   Mentions: 7  
      10. Chapter 5 - Disease and Treatment Monitoring in Diffusion MRI of the Breast. 2022; 71-85. Li, Wen Newitt, David C Partridge, Savannah C Hylton, Nola M.
      11. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer. Tomography. 2022 04 22; 8(3):1208-1220. Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM. PMID: 35645385; PMCID: PMC9149942.
        View in: PubMed   Mentions: 2     Fields:    Translation:Humans
      12. The Clinical Variant Analysis Tool: Analyzing the evidence supporting reported genomic variation in clinical practice. Genet Med. 2022 07; 24(7):1512-1522. Chin HL, Gazzaz N, Huynh S, Handra I, Warnock L, Moller-Hansen A, Boerkoel P, Jacobsen JOB, du Souich C, Zhang N, Shefchek K, Prentice LM, Washington N, Haendel M, Armstrong L, Clarke L, Li WL, Smedley D, Robinson PN, Boerkoel CF. PMID: 35442193; PMCID: PMC9363005.
        View in: PubMed   Mentions: 2     Fields:    Translation:Humans
      13. Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response. Tomography. 2022 03 22; 8(2):891-904. Nguyen AA, Onishi N, Carmona-Bozo J, Li W, Kornak J, Newitt DC, Hylton NM. PMID: 35448706; PMCID: PMC9027600.
        View in: PubMed   Mentions: 1     Fields:    Translation:Humans
      14. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308. Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM. PMID: 34427465; PMCID: PMC8574064.
        View in: PubMed   Mentions: 9     Fields:    Translation:Humans
      15. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021 Mar 25; 7(1):32. Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L. PMID: 33767190; PMCID: PMC7994408.
        View in: PubMed   Mentions: 24  
      16. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Sci Rep. 2020 12 14; 10(1):21930. Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF. PMID: 33318514; PMCID: PMC7736887.
        View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
      17. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. NPJ Breast Cancer. 2020 Nov 27; 6(1):63. Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM. PMID: 33298938; PMCID: PMC7695723.
        View in: PubMed   Mentions: 20  
      18. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients. J Breast Imaging. 2020 Aug; 2(4):352-360. Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators. PMID: 32803155; PMCID: PMC7418876.
        View in: PubMed   Mentions: 4     Fields:    
      19. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial. Tomography. 2020 06; 6(2):77-85. Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM. PMID: 32548283; PMCID: PMC7289255.
        View in: PubMed   Mentions: 4     Fields:    Translation:Humans
      20. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy. Tomography. 2020 06; 6(2):101-110. Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM. PMID: 32548286; PMCID: PMC7289261.
        View in: PubMed   Mentions: 7     Fields:    Translation:Humans
      21. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. Tomography. 2020 06; 6(2):216-222. Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM. PMID: 32548299; PMCID: PMC7289243.
        View in: PubMed   Mentions: 5     Fields:    Translation:Humans
      22. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. J Magn Reson Imaging. 2019 12; 50(6):1742-1753. Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium, Esserman LJ, Hylton NM. PMID: 31026118; PMCID: PMC6815231.
        View in: PubMed   Mentions: 20     Fields:    Translation:Humans
      23. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12. Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. PMID: 31016232; PMCID: PMC6467896.
        View in: PubMed   Mentions: 12  
      24. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging. 2019 06; 49(6):1617-1628. Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators. PMID: 30350329; PMCID: PMC6524146.
        View in: PubMed   Mentions: 48     Fields:    Translation:Humans
      25. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 06; 17(3):e155-e159. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. PMID: 28110902; PMCID: PMC7337237.
        View in: PubMed   Mentions: 8     Fields:    Translation:Humans
      26. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387. Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network. PMID: 28066808; PMCID: PMC5214452.
        View in: PubMed   Mentions: 14     Fields:    
      27. Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Tomography. 2016 Dec; 2(4):438-447. Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM. PMID: 29527574; PMCID: PMC5844277.
        View in: PubMed   Mentions: 6     Fields:    
      28. The Utility of Cloud Computing in Analyzing GPU-Accelerated Deformable Image Registration of CT and CBCT Images in Head and Neck Cancer Radiation Therapy. IEEE J Transl Eng Health Med. 2016; 4:4300311. Zaki G, Plishker W, Li W, Lee J, Quon H, Wong J, Shekhar R. PMID: 32520000; PMCID: PMC6984195.
        View in: PubMed   Mentions: 1     Fields:    
      29. Variability and bias assessment in breast ADC measurement across multiple systems. J Magn Reson Imaging. 2016 10; 44(4):846-55. Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM. PMID: 27008431; PMCID: PMC5098898.
        View in: PubMed   Mentions: 13     Fields:    Translation:Humans
      30. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. PMID: 26886725; PMCID: PMC4757528.
        View in: PubMed   Mentions: 8     Fields:    Translation:Humans
      31. Automated parcellation of the brain surface generated from magnetic resonance images. Front Neuroinform. 2013; 7:23. Li W, Andreasen NC, Nopoulos P, Magnotta VA. PMID: 24155718; PMCID: PMC3804771.
        View in: PubMed   Mentions: 4  
      32. Comparison of Displacement-Based and Force-Based Mapped Meshing. Midas J. 2008 Aug 14; 2008:629. Magnotta VA, Li W, Grosland NM. PMID: 21552387; PMCID: PMC3088872.
        View in: PubMed   Mentions:
      Wen's Networks
      Concepts (75)
      Derived automatically from this person's publications.
      Explore
      _
      Co-Authors (33)
      People in Profiles who have published with this person.
      Explore
      _
      Similar People (60)
      People who share similar concepts with this person.
      Explore
      _
      Same Department
      Search Department
      _

      UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

      We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

      Copyright © The Regents of the University of California.